• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test
 
  • Détails
Titre

Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
The Journal of Clinical Endocrinology & Metabolism  
Auteur(s)
Gaillard, R. C.
Auteure/Auteur
Abeywickrama, K.
Auteure/Auteur
Brownell, J.
Auteure/Auteur
Muller, A. F.
Auteure/Auteur
Liens vers les personnes
rgaillar
Liens vers les unités
Endocrinologie diabétologie&métabo.  
ISSN
0021-972X
Statut éditorial
Publié
Date de publication
1989-02
Volume
68
Numéro
2
Première page
329
Dernière page/numéro d’article
35
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Feb
Résumé
CV 205-502, an octahydrobenzo[g]quinoline, is a dopamine agonist compound that is not an ergot or ergoline derivative. To investigate the site of action of CV 205-502, three groups of five men were given single daily doses of CV 205-502 (0.04, 0.06, or 0.08 mg/day, doses that suppress plasma PRL by 60-80% for 24 h) for 5 days; on day 6 a combined anterior pituitary function test using iv administration of four hypothalamic releasing hormones (TRH, 200 micrograms; GHRH, 100 micrograms; CRH, 100 micrograms; LHRH, 100 micrograms) was performed. One month later the challenge tests were repeated to obtain control values. The following hormones were measured by RIA in plasma: TSH, ACTH, cortisol, PRL, GH, LH, FSH, and testosterone. With the exception of plasma PRL levels, basal and releasing hormone-stimulated values were similar after CV 205-502 administration and after the 1-month washout period. Basal plasma PRL was lower after CV 205-502 administration, and the response to TRH was attenuated by all three doses of CV 205-502 (the mean percent inhibition values were 76%, 93%, and 94%, respectively). All three doses of CV 205-502 were well tolerated, and another group of men well tolerated 0.1 mg daily. The results confirm that CV 205-502 is a potent dopamine agonist, which directly inhibits lactotropic cells but has no effect on other pituitary cell types.
Sujets

Adult Aminoquinolines...

PID Serval
serval:BIB_1A20DAAE19D6
DOI
10.1210/jcem-68-2-329
PMID
2563733
WOS
A1989R947500014
Permalien
https://iris.unil.ch/handle/iris/83125
Date de création
2008-02-15T15:58:12.058Z
Date de création dans IRIS
2025-05-20T17:18:29Z
  • Copyright © 2024 UNIL
  • Informations légales